SustainabilityESG Data

Environmental

INPUT

Items Units FY2020 FY2021 FY2022 FY2023 FY2024
Energy consumption
Electricity Thousand kwh 88,772 90,196 115,948 126,457 125,539
(of which) In-house power generation Thousand kwh 2,278 2,239 1,465 852 1,375
(of which) Solar power (On-Site Power Purchase Agreement) Thousand kwh - 96 285 269 39
(of which) CO2-free electricity (Derived from non-fossil power sources) Thousand kwh - - - 8,033 15,467
Kerosene kl 1,970 1,991 1,728 2,088 1,615
Heavy oil (A type) kl 761 736 511 308 318
Light oil kl 0 0.09 0 0.17 0.14
Volatile oil kl 0 0 0 0 0.09
LPG t 4 1 2,187 1,274 1,308
LNG t 0 0 0 0 635
City gas Thousand m3 3,817 3,984 4,971 4,752 4,429
Non-industrial steam GJ 65,146 56,700 55,484 56,237 60,734
Crude oil equivalent kl 30,130 30,452 40,628 36,955 42,216
Water
Amount of water used (Clean water, industrial water, and well water used) Thousand m3 367 360 357 348 447
Per unitAmount of water used divided by production volume (unit: hundred million tablets) - 1.6 1.4 1.2 1.3 1.5
(of which) clean water Thousand m3 330 325 307 307 392
(of which) industrial water Thousand m3 37 35 50 41 50
(of which) well water Thousand m3 0 0 0 0 4

* Sawai Pharmaceutical only (before FY2020)
* Including even Kaken Shouyaku's data except water (from FY2021 onward)
* Including even Trust Pharmatech's data except water (from FY2022 onward)
* Entire Sawai Group (from FY2024 onward)

OUTPUT

Items Units FY2020 FY2021 FY2022 FY2023 FY2024
Water
Total drainage volume Thousand m3 360 353 330 324 420
(of which) sewer drainage Thousand m3 152 165 142 131 212
(of which) river drainage Thousand m3 48 39 37 38 51
(of which) Others Thousand m3 160 149 151 154 157
CO2
CO2 emission kt-CO2 50.5 53.3 67.9 73.2 81.2
(of which) CO2-free electricity (Derived from non-fossil power sources) kt-CO2 - - - 3.4 6.5
CO2 emission (After offset) kt-CO2 50.5 53.3 67.9 69.8 74.7
Per unitEmission volume (After offset) divided by production volume (unit: billion tablets) - 2.1 2.0 2.4 2.5 2.6
(of which) Scope1 CO2 emission kt-CO2 14.8 15.2 22.7 19.5 19.7
(of which) Scope2 CO2 emission (After offset) kt-CO2 35.6 38.1 46.5 50.3 55.0
Scope3 CO2 emission
Total Scope3 emissions in the value chains kt-CO2 194.6 222.5 256.6 231.2 354.3
1. Purchased goods and services kt-CO2 156.8 188.9 198.7 198.4 217.7
2. Capital goods kt-CO2 17.6 12.2 36.0 10.8 113.6
3. Fuel-and energy-related activities (not included in scope 1 or scope 2) kt-CO2 8.0 7.8 8.1 8.3 10.5
4. Upstream transportation and distribution kt-CO2 N/A N/A N/A N/A N/A
5. Waste generated in operations kt-CO2 0.9 1.0 1.1 1.1 1.2
6. Business travel kt-CO2 0.2 0.2 0.2 0.2 0.3
7. Employee commuting kt-CO2 0.9 0.9 1.1 1.1 1.5
8. Upstream leased assets kt-CO2 N/A N/A N/A N/A N/A
9. Downstream transportation and distribution kt-CO2 9.8 10.7 10.3 10.3 9.1
10. Processing of sold products kt-CO2 N/A N/A N/A N/A N/A
11. Use of sold products kt-CO2 N/A N/A N/A N/A N/A
12. End-of-life treatment of sold products kt-CO2 N/A N/A N/A N/A N/A
13. Downstream leased assets kt-CO2 N/A N/A N/A N/A N/A
14. Franchises kt-CO2 N/A N/A N/A N/A N/A
15. Investments kt-CO2 0.5 0.8 1.1 1.1 0.5
Waste
Amount of waste, etc. t 1,981 2,094 2,285 2,338 2,354
Per unitDischarge amount divided by production volume (unit: hundred million tablets) - 8.4 7.9 7.9 7.6 8.1
Recycled volume t 946 1,363 1,508 1,323 1,304
Recycling rate % 48 65 66 57 55
Chemical substances, etc.
Amount of release and transfer of specified chemical substances
Subjects: acetonitrile and methylene chloride (dichloromethane) (before FY2022)
methylene chloride (dichloromethane), xylene, trimethylbenzene, methylnaphthalene (from FY2023 onward)
Clarithromycin added (from FY2024 onward) 		t 27 31 32 13 15
NOx t 18 20 5 4 13
SOx t 1 1 1 0.3 0.3

* Sawai Pharmaceutical only (before FY2020)
* Including even Kaken Shouyaku's data except water and Scope3 CO2 emission (from FY2021 onward)
* Including even Trust Pharmatech's data except water and Scope3 CO2 emission (from FY2022 onward)
* Entire Sawai Group (from FY2024 onward)

Social

Status of Employees

Items Units FY2020 FY2021 FY2022 FY2023 FY2024
Number of Employees*1 Persons 2,444 2,474 2,944 3,037 3,310
Manufacturing Persons 1,607 1,636 2,015 2,097 2,374
R&D Persons 246 253 295 297 300
Administration, Sales Persons 591 585 634 643 636
Male Persons 1,642 1,663 1,920 1,961 2,150
Female Persons 802 811 1,024 1,076 1,160
Male (Ratio) % 67.2 67.2 65.2 64.6 65.0
Female (Ratio) % 32.8 32.8 34.8 35.4 35.0
Average number of temporary employees Persons 298 310 328 333 339
Number of employees in managerial positions*1 Persons 258 256 262 288 325
Number of MRs Persons 382 379 375 376 375
Number of persons with pharmacist qualifications*2 Persons 256 255 246 266 295
Mean age*3 Age 38.6 38.8 38.2 38.2 39.4
Male Age 38.7 38.6 38.2 38.3 39.5
Female Age 38.6 39.0 38.0 37.8 39.4
Average length of service*3 Years 8.9 9.3 8.9 8.6 8.8
Male Years 9.1 9.5 9.2 9.0 9.2
Female Years 8.5 8.8 8.3 7.7 8.1
Number of recruits*3 Persons 76 166 201 242 430
Hiring of new graduates Persons 10 49 83 95 109
(of which) Male Persons 5 33 44 58 62
(of which) Female Persons 5 16 39 37 47
New employees transferred from other company, etc. Persons 66 117 118 147 321
(of which) Male Persons 28 79 82 87 230
(of which) Female Persons 38 38 36 60 91
Employee turnover*3 % 2.8 3.3 3.1 4.1 5.0
Retention of new graduates (at the time after 3years of employment)*4 % 94.7 92.9 93.7 94.3 93.4
Salary and benefit*5 Million yen 5,132 661 722 717 915
Ratio of employees covered by the collective agreements*1 % 89.4 89.7 91.1 90.5 90.2
Unionization rate (Sawai Pharmaceutical Workers Union)*1 % 77.1 80.5 85.1 86.1 99.2

*1 Sawai Pharmaceutical, Medisa Shinyaku and Kaken Shoyaku, Trust Pharmatech (from FY2022 onward)
*2 Sawai Pharmaceutical and Kaken Shoyaku, Trust Pharmatech (from FY2022 onward)
*3 Sawai Pharmaceutical only (before FY2022), Sawai Group Domestic Only (FY2023), Entire Sawai Group (from FY2024 onward)
*4 Sawai Pharmaceutical only (before FY2023), Entire Sawai Group (from FY2024 onward)
*5 Sawai Pharmaceutical (before FY2020), Sawai Group Holdings (from FY2021 onward)

Diversity Promotion

Items Units FY2020 FY2021 FY2022 FY2023 FY2024
Number of foreign national employees*1 Persons 6 7 7 8 9
Number of female employees in managerial positions*1 Persons 15 17 18 24 31
Ratio of female employees in managerial positions*2 % 5.8 6.6 6.9 8.3 9.5
Ratio of disabled employees*3 % 2.48 2.38 2.57 2.54 2.79
Number of employees rehired after retirement*4 Persons 43 59 78 103 117
Percentage of rehired employees who retired at retirement age*4 % 95.2 87.5 96.4 81.8 98.3
Percentage of mid-career employees in managerial positions*4 % 56.0 61.0 63.0 60.9 63.6

*1 Sawai Pharmaceutical only (before FY2022), Sawai Group Domestic Only (FY2023), Entire Sawai Group (from FY2024 onward)
*2 Sawai Pharmaceutical only (before FY2022), Sawai Group Domestic Only (FY2023), Entire Sawai Group (from FY2024 onward). Target ratio of female employees in managerial positions: 15% and above by the end of March 2027.
*3 Target: To maintain the level over the statutory employment ratio of disabled employees. The statutory employment ratio for disabled employees since April 2025 is 2.7%. The figures are as of June 1 of the following year.
*4 Sawai Pharmaceutical only (before FY2023), Entire Sawai Group (from FY2024 onward)

Work Environment

Items Units FY2020 FY2021 FY2022 FY2023 FY2024
Paid leave utilization rate*1 % 72.9 71.1 80.5 82.2 81.3
Number of employees who take child-care leave*2 Persons 74 42 49 82 100
(of which) Male Persons - 10 20 38 40
(of which) Female Persons - 32 29 44 60
Child-care leave utilization rate*3 % 2.7 34.7 50.0 55.0 67.1
Return rate from child-care leave*4 % 91.7 100 100 100 100
Number of employees who take family-care leave*5 Persons 3 0 1 3 0
Average hours of overtime work per month*5 Hours 16.5 17.7 15.8 15.8 16.8
Stress check examination rate*4 % - 97.6 97.8 98.1 97.5
Medical checkup rate*5 % - 100 100 100 100
Smokers rate*4 % 13.7 12.8 12.7 11.9 11.7
Frequency rate of occupational injuries*4 % 0 0 0.54 0.89 0.66

*1 Eligible Persons: Union members, Terms: From 1st Jan. to 31st Dec. Sawai Pharmaceutical only (before FY2023), Entire Sawai Group (from FY2024 onward)
*2 Excluding Kaken Shouyaku (before FY2023), Entire Sawai Group (from FY2024 onward)
*3 Denominator is the number of employees as of the end of March. (before FY2020), Denominator is the number of employees who gave birth to children by themselves or their spouses among Sawai-registered or transferred employees to Sawai (from FY2021 to 2023), Entire Sawai Group (from FY2024 onward).
*4 Sawai Pharmaceutical only
*5 Sawai Pharmaceutical only (before FY2023), Entire Sawai Group (from FY2024 onward)

Employee Growth

Items Units FY2020 FY2021 FY2022 FY2023 FY2024
Number of employees trained*1 Persons 4,038 2,840 4,034 3,795 5,842
Employee training expenses*2 Million yen 45 63 88 92 91
Pass rate of MR certification test*2 % is not applicable is not applicable 100 100 100

*1 Sawai Pharmaceutical only (before FY2020), Sawai Group Domestic Only (from FY2021 onward), Entire Sawai Group (from FY2024 onward)
*2 Sawai Pharmaceutical, Medisa Shinyaku and Kaken Shoyaku

Products / Stable Supply

Items Units FY2020 FY2021 FY2022 FY2023 FY2024
Number of products*1 Items 780 790 790 770 750
Number of new products launched*2 - 19 generic drugs with 44 strengths 13 generic drugs with 32 strengths 11 generic drugs with 23 strengths 3 generic drugs with 10 strengths 7 generic drugs with 13 strengths
Number of tablets sold*2 Billion tablets 13.3 14.8 15.0 15.7 16.1
Number of patents owned*2 Items 37 42 45 53 69
Number of patents pending*2 Cases 38 44 32 30 46
Number of raw material supplier audits*3 Times 120 168 212 153 129
Number of inquiries to drug information center*2 Cases 48,600 49,800 46,700 46,468 45,758
Number of out of stock products*2 Items 8 16 6 16 19
Product recall (Class Ⅰ)*3 Cases 0 0 0 0 0
Product recall (Class Ⅱ)*3 Cases 7 8 5 11 8
Product recall (Class Ⅲ)*3 Cases 0 0 0 0 0

*1 Sawai Pharmaceutical (The figures are as of April 1 of the following year)
*2 Sawai Pharmaceutical
*3 Sawai Pharmaceutical (before FY2020), Sawai Group in Japan (from FY2021 onward)

Promotion of Communication

Items Units FY2020 FY2021 FY2022 FY2023 FY2024
Dialogue with institutional investors and analysts*1 Times 129 141 154 191 248
Communication with Mass Media*2 Times 28 42 59 38 27
Factory tours Times 16 12 45 113 85
Expenditures for social contribution activities Million yen 51 212 220 259 98

*1 Total
*2 Interview, brief session, etc.

Medical cost-saving impact

Items Units FY2020 FY2021 FY2022 FY2023 FY2024
Medical cost-saving impact Billion yen 317.6 338.2 280.9 293.9 220.3

Governance

Items Units FY2020 FY2021 FY2022 FY2023 FY2024
Number of directors (board members) Persons 6 6 6 5 5
Number of external directors Persons 2 2 2 3 3
Ratio of external directors % 33.3 33.3 33.3 60.0 60.0
Number of female directors Persons 1 1 1 1 1
Ratio of female directors % 16.7 16.7 16.7 20.0 20.0
Number of Audit & Supervisory Board members Persons 3 3 3 3 3
Number of external Audit & Supervisory Board members Persons 2 2 2 2 2
Ratio of external Audit & Supervisory Board members % 66.7 66.7 66.7 66.7 66.7
Number of corporate officers Persons 12 8 11 8 9
(of which) Number of female corporate officers Persons 1 0 1 1 1
Number of board meetings Times 16 13 13 14 14
Number of attendances of external directors
Masatoshi Ohara Attendance/Total
%		 16/16
100%		 13/13
100%		 13/13
100%		 13/14
92.9%		 11/14
78.6%
Nawomi Todo Attendance/Total
%		 16/16
100%		 13/13
100%		 13/13
100%		 14/14
100%		 14/14
100%
Masayuki Mitsuka Attendance/Total
%		 - - - 11/11
100%		 14/14
100%
Number of attendances of external Audit & Supervisory Board members
Takanobu Tomohiro Attendance/Total
%		 14/16
87.5%		 13/13
100%		 13/13
100%		 14/14
100%		 13/14
92.9%
Junichi Hirano Attendance/Total
%		 15/16
93.8%		 13/13
100%		 13/13
100%		 14/14
100%		 14/14
100%
Number of Audit & Supervisory Board meetings Times 18 16 13 13 15
Number of attendances of external Audit & Supervisory Board members
Takanobu Tomohiro Attendance/Total
%		 16/18
88.9%		 16/16
100%		 13/13
100%		 13/13
100%		 15/15
100%
Junichi Hirano Attendance/Total
%		 17/18
94.4%		 16/16
100%		 13/13
100%		 13/13
100%		 15/15
100%
Number of matters to be resolved at the board meeting Cases 106 77 71 82 71
Number of matters to be reported at the board meeting Cases 92 62 53 74 100
Total compensation allocation for directors (board members) and Audit & Supervisory Board members
Number of eligible directors (excluding outside directors) Persons 5 4 4 5 2
Total compensation allocation Million yen 299 177 292 118 98
(of which) Fixed compensation Million yen 205 177 153 77 57
(of which) Stock options Million yen 24 - 84 15 21
(of which) Performance-based compensation Million yen 70 - 55 26 20
Number of eligible Audit & Supervisory Board members (excluding outside Audit & Supervisory Board members) Persons 2 1 1 1 1
Total compensation Million yen 18 17 17 18 18
(of which) Fixed compensation Million yen 18 17 17 18 18
Number of eligible outside directors and outside Audit & Supervisory Board members Persons 4 4 4 5 5
Total compensation, etc. Million yen 25 28 30 42 45
(of which) Fixed compensation Million yen 25 28 30 42 45
Number of days between the dates of dispatch of the convocation notice and annual shareholder’s meeting Days 18 (Jun.)
17 (Dec.)		 Meeting not held due to the
transformation
into a holding company		 17 18 17
Number of cases of whistle-blowing (including consultation) or whistle blowers (Japan) Cases 8 7 6 7 19
Detection by price cartel (Outside Japan) Cases 0 0 0 0 0
Shut down or suspension of business caused by scandal or misconduct (Japan) Cases 0 0 0 0 0
Criminal indictments for accidents or incidents related to compliance violations (Japan) Cases 0 0 0 0 0
Detection by price cartel (Outside Japan) Cases 0 0 0 0 0
Detection by bribery (Outside Japan) Cases 0 0 0 0 0
Detection by other reasons (Outside Japan) Cases 0 0 0 0 0

* Data on Board and Audit & Supervisory Board is for Sawai Pharmaceutical (before FY2020), for Sawai Group Holdings (from FY2021 onward)

Back to Sustainability Top